» Articles » PMID: 23626950

Emerging Microfluidic Tools for Functional Cellular Immunophenotyping: a New Potential Paradigm for Immune Status Characterization

Overview
Journal Front Oncol
Specialty Oncology
Date 2013 Apr 30
PMID 23626950
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Rapid, accurate, and quantitative characterization of immune status of patients is of utmost importance for disease diagnosis and prognosis, evaluating efficacy of immunotherapeutics and tailoring drug treatments. Immune status of patients is often dynamic and patient-specific, and such complex heterogeneity has made accurate, real-time measurements of patient immune status challenging in the clinical setting. Recent advances in microfluidics have demonstrated promising applications of the technology for immune monitoring with minimum sample requirements and rapid functional immunophenotyping capability. This review will highlight recent developments of microfluidic platforms that can perform rapid and accurate cellular functional assays on patient immune cells. We will also discuss the future potential of integrated microfluidics to perform rapid, accurate, and sensitive cellular functional assays at a single-cell resolution on different types or subpopulations of immune cells, to provide an unprecedented level of information depth on the distribution of immune cell functionalities. We envision that such microfluidic immunophenotyping tools will allow for comprehensive and systems-level immunomonitoring, unlocking the potential to transform experimental clinical immunology into an information-rich science.

Citing Articles

A Microfluidics Approach for Ovarian Cancer Immune Monitoring in an Outpatient Setting.

Libbrecht S, Vankerckhoven A, de Wijs K, Baert T, Thirion G, Vandenbrande K Cells. 2024; 13(1).

PMID: 38201211 PMC: 10778191. DOI: 10.3390/cells13010007.


Mass-producible microporous silicon membranes for specific leukocyte subset isolation, immunophenotyping, and personalized immunomodulatory drug screening in vitro.

Stephens A, Nidetz R, Mesyngier N, Chung M, Song Y, Fu J Lab Chip. 2019; 19(18):3065-3076.

PMID: 31389447 PMC: 6736731. DOI: 10.1039/c9lc00315k.


Immunological analysis of phase II glioblastoma dendritic cell vaccine (Audencel) trial: immune system characteristics influence outcome and Audencel up-regulates Th1-related immunovariables.

Erhart F, Buchroithner J, Reitermaier R, Fischhuber K, Klingenbrunner S, Sloma I Acta Neuropathol Commun. 2018; 6(1):135.

PMID: 30518425 PMC: 6280511. DOI: 10.1186/s40478-018-0621-2.


A fluorescent microbead-based microfluidic immunoassay chip for immune cell cytokine secretion quantification.

Cui X, Liu Y, Hu D, Qian W, Tin C, Sun D Lab Chip. 2018; 18(3):522-531.

PMID: 29326990 PMC: 11517320. DOI: 10.1039/c7lc01183k.


Accelerated Biofluid Filling in Complex Microfluidic Networks by Vacuum-Pressure Accelerated Movement (V-PAM).

Yu Z, Cheung M, Liu S, Fu J Small. 2016; 12(33):4521-30.

PMID: 27409528 PMC: 6215695. DOI: 10.1002/smll.201601231.


References
1.
OShea J, Hunter C, Germain R . T cell heterogeneity: firmly fixed, predominantly plastic or merely malleable?. Nat Immunol. 2008; 9(5):450-3. DOI: 10.1038/ni0508-450. View

2.
Han Q, Bagheri N, Bradshaw E, Hafler D, Lauffenburger D, Love J . Polyfunctional responses by human T cells result from sequential release of cytokines. Proc Natl Acad Sci U S A. 2011; 109(5):1607-12. PMC: 3277116. DOI: 10.1073/pnas.1117194109. View

3.
Stern E, Klemic J, Routenberg D, Wyrembak P, Turner-Evans D, Hamilton A . Label-free immunodetection with CMOS-compatible semiconducting nanowires. Nature. 2007; 445(7127):519-22. DOI: 10.1038/nature05498. View

4.
Chen W, Huang N, Oh B, Lam R, Fan R, Cornell T . Surface-micromachined microfiltration membranes for efficient isolation and functional immunophenotyping of subpopulations of immune cells. Adv Healthc Mater. 2013; 2(7):965-975. PMC: 4459734. DOI: 10.1002/adhm.201200378. View

5.
Cornell T, Sun L, Hall M, Gurney J, Ashbrook M, Ohye R . Clinical implications and molecular mechanisms of immunoparalysis after cardiopulmonary bypass. J Thorac Cardiovasc Surg. 2011; 143(5):1160-1166.e1. PMC: 3262077. DOI: 10.1016/j.jtcvs.2011.09.011. View